Riverhead Capital Management LLC grew its stake in shares of Mylan (NASDAQ:MYL) by 160.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,742 shares of the company’s stock after buying an additional 12,775 shares during the period. Riverhead Capital Management LLC’s holdings in Mylan were worth $854,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Rational Advisors LLC bought a new position in shares of Mylan during the 4th quarter valued at about $190,000. First Personal Financial Services lifted its stake in Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after acquiring an additional 2,106 shares in the last quarter. Lombard Odier Asset Management Europe Ltd bought a new stake in Mylan in the 4th quarter valued at approximately $209,000. Mycio Wealth Partners LLC bought a new stake in Mylan in the 4th quarter valued at approximately $212,000. Finally, Advisor Partners LLC bought a new stake in Mylan in the 4th quarter valued at approximately $214,000. Hedge funds and other institutional investors own 83.66% of the company’s stock.
Mylan opened at $39.21 on Wednesday, MarketBeat.com reports. The company has a market cap of $20.39 billion, a price-to-earnings ratio of 8.60, a P/E/G ratio of 1.28 and a beta of 1.35. Mylan has a twelve month low of $29.39 and a twelve month high of $47.82. The company has a current ratio of 1.06, a quick ratio of 0.65 and a debt-to-equity ratio of 1.03.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, May 9th. The company reported $0.96 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.99 by ($0.03). The company had revenue of $2.68 billion for the quarter, compared to analyst estimates of $2.74 billion. Mylan had a return on equity of 18.56% and a net margin of 6.04%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned $0.93 EPS. research analysts forecast that Mylan will post 5.36 EPS for the current fiscal year.
MYL has been the topic of several research reports. ValuEngine cut Mylan from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Susquehanna Bancshares restated a “positive” rating and issued a $55.00 target price (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. Morgan Stanley set a $50.00 target price on Mylan and gave the company a “buy” rating in a research note on Monday, April 9th. Cantor Fitzgerald set a $41.00 target price on Mylan and gave the company a “hold” rating in a research note on Thursday, March 1st. Finally, TheStreet cut Mylan from a “b-” rating to a “c+” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $46.86.
In related news, insider Anthony Mauro sold 12,257 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $40.35, for a total transaction of $494,569.95. Following the transaction, the insider now directly owns 147,435 shares of the company’s stock, valued at approximately $5,949,002.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul Campbell sold 7,030 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total value of $309,390.30. Following the transaction, the insider now directly owns 17,054 shares in the company, valued at $750,546.54. The disclosure for this sale can be found here. Insiders have sold a total of 269,287 shares of company stock worth $11,034,960 in the last ninety days. Insiders own 0.69% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.